---
title: "NHS Framework for the North of England, Branded Medicine"
ocid: "ocds-h6vhtk-02e103"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02e103"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-02e103.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-02e103.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)"
published: "2022-03-01"
---

# NHS Framework for the North of England, Branded Medicine

Buyer: THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)  
Current stage: Award  
OCID: ocds-h6vhtk-02e103

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02e103)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-02e103.json)

## Summary

The NHS Commissioning Board, operating under the name of NHS England, has initiated a tender titled "NHS Framework for the North of England, Branded Medicines," specified under the CPV classification for Pharmaceutical products. This procurement process is currently at the Tender stage, with lots including Tranche B and various other related products. The contract period spans from 1 March 2022 to 29 February 2024, with potential extensions of up to 24 months at the authority's discretion. Important dates include the tender end date of 20 October 2021, which marks the deadline for expressions of interest and bid submissions through the specified eTendering portal.

This tender presents significant opportunities for pharmaceutical businesses, particularly those focused on branded medicines and biosimilars. Suppliers capable of delivering pharmaceutical products efficiently and complying with NHS regulations will find this procurement especially advantageous. Both large enterprises and small to medium-sized enterprises (SMEs) can compete for contracts listed under this framework, allowing for collaboration and participation in a diversified marketplace that is critical for growth in the healthcare sector.

## Notice

HS Framework for the North of England, Branded Medicines - Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi(r))

### Lot Information

CM/PHR/20/5600/01 - NHS Framework for the NOFE, Branded Medicines - Tranche B

CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/20/5600/02 - NHS Framework for the NOFE, Branded Medicines-Annual Tranche

CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi(r))-SofE

CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi(r)), South of England - Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 6 months.

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 6 months.

CM/PHR/20/5600/04-NHS Framework for Insulin Aspart Biosimilar (Trurapi(r)), London

CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi(r)), London - Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 18 months.

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 18 months.

CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi(r)), MaE

CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi(r)), Midlands and East - Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/005550-2022 |
| Notice type | Tender Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Large, SME |
| All stages | Tender, Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 1 Mar 2022 |
| Submission deadline | 20 Oct 2021 |
| Future notice date | Not specified |
| Award date | 7 Feb 2022 |
| Contract period | 1 Mar 2022 - 28 Feb 2023 |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | £863,999,552 |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £1 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Cancelled |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND) |
| Locality | RUNCORN |
| Post town | Warrington |
| Postcode | WA7 2ES |
| Country | England |
| ITL 1 | TLD North West (England) |
| ITL 2 | TLD7 Merseyside |
| ITL 3 | TLD71 East Merseyside |
| Local authority | Halton |
| Electoral ward | Halton Lea |
| Westminster constituency | Runcorn and Helsby |
| Delivery location | Not specified |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 27 |
| Supplier names | ACCORD-UK; AMGEN; AVENTIS PHARMA LTD T/A SANOFI; BAYER; BIOGEN; BRISTOL MYERS SQUIBB; CELLTRION HEALTHCARE UNITED KINGDOM; CST PHARMA; ELI LILLY; GEDEON RICHTER; GILEAD SCIENCES; GLAXOSMITHKLINE; IPSEN; JANSSEN-CILAG; MERCK SERONO; MERCK SHARPE AND DOHME (UK; NAPP PHARMACEUTICALS; NOVO NORDISK; PFIZER; ROCHE PRODUCTS; SOBI (SWEDISH ORPHAN BIOVITRUM; TAKEDA; TEVA; THORNTON AND ROSS; UCB PHARMA; UL GLOBAL PHARMA; ZENTIVA PHARMA |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33600000 - Pharmaceutical products

## Release History

- 1 Mar 2022 at 12:15 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/005550-2022
- 15 Sep 2021 at 12:10 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/022928-2021

## Notice URLs

- http://health.atamis.co.uk
- http://health.atamis.co.ukCandidates
- https://supplierregistration.cabinetoffice.gov.ukand
- https://www.england.nhs.uk/
- https://www.gov.uk/courts-tribunals

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02e103. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-02e103.json.